Wuxi Laitakang closes Series A and A+ to advance myeloid cell tech

What's the deal? Chinese biopharmaceutical company Wuxi LaitakangDealroom has a profile for this one. Try Dealroom → has closed Series A and Series A+ financing rounds, the company said on September 20. Cathay CapitalDealroom has a profile for this one. Try Dealroom → led the Series A round, with CICC CapitalDealroom has a profile for this one. Try Dealroom →'s CICC Norsgar FundDealroom has a profile for this one. Try Dealroom → participating.

Who else is in? Huagai CapitalDealroom has a profile for this one. Try Dealroom → led the Series A+ round, joined by Shenzhen Capital Group and CICC Strategy.

What's the endgame? Wuxi Laitakang will use the money to accelerate the clinical translation of its myeloid cell bridging technology.

The signal: The backing from Cathay Capital, alongside state-linked Shenzhen Capital Group and CICC's investment arms, points to continued institutional appetite for early-stage Chinese biopharma innovation.

Read more: longbridge.com

Image credit: National Institutes of Health (NIH)